Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy PTC Therapeutics stock
Learn how to easily invest in PTC Therapeutics stock.
PTC Therapeutics Inc is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. PTC Therapeutics employs 959 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in PTC Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTCT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
PTC Therapeutics stock price (NASDAQ: PTCT)Use our graph to track the performance of PTCT stocks over time.
PTC Therapeutics shares at a glance
|Latest market close||$43.75|
|52-week range||$34.85 - $69.48|
|50-day moving average||$39.05|
|200-day moving average||$40.84|
|Wall St. target price||$52.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.50|
Buy PTC Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy PTC Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
PTC Therapeutics price performance over time
|1 week (2022-01-06)||12.44%|
|1 month (2021-12-16)||19.60%|
|3 months (2021-10-15)||14.86%|
|6 months (2021-07-16)||1.34%|
|1 year (2021-01-15)||-36.12%|
|2 years (2020-01-16)||-16.62%|
|3 years (2019-01-16)||25.47%|
|5 years (2017-01-13)||182.81%|
Is PTC Therapeutics stock undervalued or overvalued?
Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PTC Therapeutics's PEG ratio
PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PTC Therapeutics financials
|Revenue TTM||$492.2 million|
|Gross profit TTM||$-62,219,000|
|Return on assets TTM||-10.35%|
|Return on equity TTM||-147.75%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
PTC Therapeutics share dividends
We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.
PTC Therapeutics share price volatility
Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $34.85 up to $69.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 0.8936. This would suggest that PTC Therapeutics's shares are less volatile than average (for this exchange).
PTC Therapeutics overview
PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F.
PTC Therapeutics in the news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program
Frequently asked questionsWhat percentage of PTC Therapeutics is owned by insiders or institutions?
Currently 2.983% of PTC Therapeutics shares are held by insiders and 106.902% by institutions. How many people work for PTC Therapeutics?
Latest data suggests 959 work at PTC Therapeutics. When does the fiscal year end for PTC Therapeutics?
PTC Therapeutics's fiscal year ends in December. Where is PTC Therapeutics based?
PTC Therapeutics's address is: 100 Corporate Court, South Plainfield, NJ, United States, 07080 What is PTC Therapeutics's ISIN number?
PTC Therapeutics's international securities identification number is: US69366J2006 What is PTC Therapeutics's CUSIP number?
PTC Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69366J200
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert